SPECIFIC PROPERTIES OF ROXERA DRUG IN CARDIOVASCULAR DISEASES

Аннотация

Stroke remains one of the most important medical problems and causes of death population around the world. In the published in the 2017 collection of European statistics on cardiovascular diseases (CVD) current data on the reasons are provided deaths of men and women in Europe. However These successes are observed mainly due to countries in which the proportion of deaths from stroke is for men it is 7%, for women it is 12%. The reason for such a significant decreasemortality from CVD and stroke in the European Union, in addition to the introduction of high-tech techniques, intensive correction with the help of antihypertensive and lipid-lowering drugs is consideredsuch important CVD risk factors as arterial hypertension (AH) and dyslipidemia (DLP). Modern ideas about the role of DLP correction in the prevention of primary and recurrent stroke boil down to the fact that DLP in the form of an increase in the level of both total cholesterol, and low density lipoproteins (LDL) is associated with an increased risk ischemic stroke (IS), which accounts for approximately 80% of all strokes, but not associated with risk of fatal stroke. Keywords: Stroke, arterial hypertension, dyslipidemia DLP, total cholesterol, lipoproteins (LDL), Rosuvastatin, myocardial infarction, hospitalizations. ОСОБЕННОСТИ ПРЕПАРАТА РОКСЕРА ПРИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ Аннотация. Инсульт остается одной из важнейших медицинских проблем и причин смерти населения во всем мире. В опубликованном в 2017 году сборнике Европейской статистики по сердечно-сосудистым заболеваниям (ССЗ) приведены актуальные данные о причинах смерти мужчин и женщин в Европе. Однако эти успехи наблюдаются в основном за счет стран, в которых доля смертей от инсульта составляет для мужчин 7%, для женщин – 12%. Причиной столь существенного снижения смертности от ССЗ и инсульта в странах Евросоюза, помимо внедрения высокотехнологичных методик, считается интенсивная коррекция с помощью антигипертензивных и гиполипидемических препаратов таких важных факторов риска ССЗ, как артериальная гипертензия (АГ) и дислипидемия (ДЛП). Современные представления о роли коррекции ДЛП в профилактике первичного и повторного инсульта сводятся к тому, что ДЛП в виде повышения уровня как общего холестерина, так и липопротеидов низкой плотности (ЛПНП) ассоциируется с повышенным риском ишемического инсульта (ИИ), который составляет примерно 80% всех инсультов, но не ассоциируется с риском фатального инсульта. 472 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 2 Ключевые слова: Инсульт, артериальная гипертензия, дислипидемия ДЛП, общий холестерин, липопротеиды (ЛПНП), розувастатин, инфаркт миокарда, госпитализации. Data on the effectiveness of statin therapy in reducing the risk of IS absolutely correlate with modern recommendations. In modern guidelines for achieving targets it is recommended to prescribe statins until up to the maximum recommended or maximum tolerated dosage. A special place in performance assessment and safety of using statins for stroke prevention is a meta-analysis of several dozen clinical studies involving a total of 121 thousand patients. When prescribing statins for primary for stroke prevention, cardiovascular assessment systems are commonly used risk. It is believed that if the patient does not have CVD, then when deciding on the appointment statins should be used in risk categories such as very high risk (diabetes mellitus (DM) with target organ damage or in combination with a significant risk factor. When prescribing statins for secondary stroke prevention should be taken into account that all patients with atherosclerotic CVD confirmed clinically or according to radiological diagnostic methods (post-myocardial infarction, acute coronary syndrome, revascularization surgery, stroke or transient ischemic attack (TIA), chronic lower limb ischemia) are classified as very high risk. Rosuvastatin has demonstrated the ability to reduce cardiovascular morbidity and mortality not only in patients with very high and high risk, but also in patients with moderate risk. In the recently completed HOPE-3 trial, giving rosuvastatin 10 mg vs placebo to intermediate-risk patients resulted in a reduction in the incidence of the first primary endpoint. points – cardiovascular death/myocardial infarction/stroke (3.7 vs 4.8%; RR0.76; 95% CI 0.64–0.91; p = 0.002) and second primary endpoint – cardiovascular death/myocardial infarction/stroke/sudden death/heart failure/revascularization (4.4 vs 5.7%; RR 0.75; 95% CI 0.64–0.88; p < 0.001) [19]. For secondary endpoints rosuvastatin was also effective: there was a reduction in the incidence of coronary heart disease (1.7 vs 2.2%; p = 0.02) and hospitalizations (4.4 vs 5.8%; p < 0.001) The invention relates to the field of medicine, in particular to the pharmaceutical industry, and describes a solid dosage form with hypolipidemic action containing rosuvastatin or its pharmaceutically acceptable salt in an amount of 3 to 15%, tech